Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8675MR)

This product GTTS-WQ8675MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8675MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5114MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ3825MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ3040MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ15876MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ5764MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ350MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ585MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ14687MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW